Sinovac Biotech (SVA) 5.02 $SVA
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 28.32 (-0.74), MDT: 78.02 (+0.36), RARE: 62.06 (-0.83), PFE: 34.25 (+0.10), SUPN: 11.35 (-0.11), NRX: 7.41 (-0.12), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), SVA: 5.02 (+0.03), BLRX: 2.06 (+0.03), AMPH: 14.74 (+0.30), CHRS: 26.46 (-2.27), JNJ: 102.40 (+0.71), GNVC: 3.16 (+0.07), CYCC: 0.98 (+0.02), AZN: 72.70 (+1.80), DPRX: 14.00 (+0.49), TEVA: 62.10 (+0.55), NBY: 0.61 (-0.02)
Simavita Updates on New Agreements, Pilots and Key Appointments
Marketwired - Wed Mar 18, 10:06AM CDT
Highlights
SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Sinovac to Participate in China Medical and Healthcare Investment Conference
PR Newswire - Wed Mar 18, 5:00AM CDT
Sinovac Biotech Ltd.(NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company will participate in the China Medical and Healthcare Investment Conference sponsored by T.H capital and Dong Xing Security, to be held at China World Hotel from March 23 to March 25. The Company will present from 09:30 am to 10:30am on March 25, and conduct one-on-one meetings during the course of the day. Any parties interested in scheduling a meeting with the Company at this event should contact T.H capital or Dong Xing Security.
SVA: 5.02 (+0.03)
Sinovac Provides Updates on Pipeline Vaccines
PR Newswire - Tue Mar 17, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today provided updates on the Company's pipeline vaccines.
SVA: 5.02 (+0.03)
Simavita Limited: Proposed Appointment of Warren Bingham as Director
Marketwired - Fri Mar 13, 11:08AM CDT
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to announce the proposed appointment of Mr. Warren Bingham as a Director of the Company. Mr. Bingham's appointment is subject to TSX-V approval as well as shareholder approval which will be sought at a Special Meeting that the Company anticipates will be held in late April / early May 2015.
SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Hand, Foot And Mouth Disease Therapeutics Pipeline Review 2015 - 6 Companies & 6 Drug Profiles
M2 - Wed Mar 11, 6:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qjqznd/hand_foot_and) has announced the addition of the "Hand, Foot And Mouth Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hand, Foot And Mouth Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hand, Foot And Mouth Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Chongqing Zhifei Biological Products Co., Ltd. - CJ CheilJedang Corp. - iQur Ltd. - Sentinext Therapeutics Sdn Bhd - Sinovac Biotech Ltd. - Takeda Pharmaceutical Company Limited Drug Profiles - CJ-40010 - enterovirus [type 71] vaccine - foot and mouth disease virus like particle vaccine - hand foot and mouth disease vaccine - hand, foot and mouth (bivalent) viral like particle vaccine - INV-21 For more information visit http://www.researchandmarkets.com/research/qj...d_foot_and
SVA: 5.02 (+0.03)
Simavita Receives $1.37 Million Cash Payment Under R&D Tax Incentive Scheme
Marketwired - Thu Feb 05, 9:19AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company" is pleased to confirm the receipt of $1,370,468 under the Australian Government's Research and Development Tax Incentive Scheme. The claim covers the year ended 30 June 2014.
SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Simavita Limited: Philippa Lewis Discusses the Abena Distribution Agreement and Appendix 4C
Marketwired - Wed Feb 04, 10:30AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company" is pleased to invite investors to listen to an audio recording of CEO, Ms. Philippa Lewis, providing further background to the Company's announcement released on January 29, 2015, entitled "Simavita signs up Danish distributor", and the Company's quarterly cash flow report, which was released on January 30, 2015.
SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
ASX Appendix 4C for the Quarter Ended December 31, 2014
Marketwired - Fri Jan 30, 10:38AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company" is pleased to release its ASX Appendix 4C for the quarter ended December 31, 2014.
SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Simavita Limited: Exclusive Agreement With Danish Distributor Executed and First Sales Recorded
Marketwired - Thu Jan 29, 10:41AM CST
Highlights:
SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Simavita Limited: Release of Securities from Escrow
Marketwired - Tue Jan 20, 10:21AM CST
Simavita Limited (ASX: SVA) (TSX VENTURE: SV) advises that a total of 1,155,298 warrants in the Company will be released from escrow on January 31, 2015.
SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Simavita Appoints New Chairman
Marketwired - Wed Jan 07, 12:33PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company" is pleased to advise of the appointment of Mr. Michael Brown as a Director of the Company and as its Chairman of the Board.
SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 28.32 (-0.74), MDT: 78.02 (+0.36), RARE: 62.06 (-0.83), PFE: 34.25 (+0.10), SUPN: 11.35 (-0.11), NRX: 7.41 (-0.12), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), SVA: 5.02 (+0.03), BLRX: 2.06 (+0.03), AMPH: 14.74 (+0.30), CHRS: 26.46 (-2.27), JNJ: 102.40 (+0.71), GNVC: 3.16 (+0.07), CYCC: 0.98 (+0.02), AZN: 72.70 (+1.80), DPRX: 14.00 (+0.49), TEVA: 62.10 (+0.55), NBY: 0.61 (-0.02)
Simavita Updates on New Agreements, Pilots and Key Appointments
Marketwired - Wed Mar 18, 10:06AM CDT
Highlights
SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Sinovac to Participate in China Medical and Healthcare Investment Conference
PR Newswire - Wed Mar 18, 5:00AM CDT
Sinovac Biotech Ltd.(NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company will participate in the China Medical and Healthcare Investment Conference sponsored by T.H capital and Dong Xing Security, to be held at China World Hotel from March 23 to March 25. The Company will present from 09:30 am to 10:30am on March 25, and conduct one-on-one meetings during the course of the day. Any parties interested in scheduling a meeting with the Company at this event should contact T.H capital or Dong Xing Security.
SVA: 5.02 (+0.03)
Sinovac Provides Updates on Pipeline Vaccines
PR Newswire - Tue Mar 17, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today provided updates on the Company's pipeline vaccines.
SVA: 5.02 (+0.03)
Simavita Limited: Proposed Appointment of Warren Bingham as Director
Marketwired - Fri Mar 13, 11:08AM CDT
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to announce the proposed appointment of Mr. Warren Bingham as a Director of the Company. Mr. Bingham's appointment is subject to TSX-V approval as well as shareholder approval which will be sought at a Special Meeting that the Company anticipates will be held in late April / early May 2015. SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Hand, Foot And Mouth Disease Therapeutics Pipeline Review 2015 - 6 Companies & 6 Drug Profiles
M2 - Wed Mar 11, 6:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qjqznd/hand_foot_and) has announced the addition of the "Hand, Foot And Mouth Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hand, Foot And Mouth Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hand, Foot And Mouth Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Chongqing Zhifei Biological Products Co., Ltd. - CJ CheilJedang Corp. - iQur Ltd. - Sentinext Therapeutics Sdn Bhd - Sinovac Biotech Ltd. - Takeda Pharmaceutical Company Limited Drug Profiles - CJ-40010 - enterovirus [type 71] vaccine - foot and mouth disease virus like particle vaccine - hand foot and mouth disease vaccine - hand, foot and mouth (bivalent) viral like particle vaccine - INV-21 For more information visit http://www.researchandmarkets.com/research/qj...d_foot_and
SVA: 5.02 (+0.03)
Simavita Receives $1.37 Million Cash Payment Under R&D Tax Incentive Scheme
Marketwired - Thu Feb 05, 9:19AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to confirm the receipt of $1,370,468 under the Australian Government's Research and Development Tax Incentive Scheme. The claim covers the year ended 30 June 2014. SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Simavita Limited: Philippa Lewis Discusses the Abena Distribution Agreement and Appendix 4C
Marketwired - Wed Feb 04, 10:30AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to invite investors to listen to an audio recording of CEO, Ms. Philippa Lewis, providing further background to the Company's announcement released on January 29, 2015, entitled "Simavita signs up Danish distributor", and the Company's quarterly cash flow report, which was released on January 30, 2015. SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
ASX Appendix 4C for the Quarter Ended December 31, 2014
Marketwired - Fri Jan 30, 10:38AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to release its ASX Appendix 4C for the quarter ended December 31, 2014. SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Simavita Limited: Exclusive Agreement With Danish Distributor Executed and First Sales Recorded
Marketwired - Thu Jan 29, 10:41AM CST
Highlights:
SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Simavita Limited: Release of Securities from Escrow
Marketwired - Tue Jan 20, 10:21AM CST
Simavita Limited (ASX: SVA) (TSX VENTURE: SV) advises that a total of 1,155,298 warrants in the Company will be released from escrow on January 31, 2015.
SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
Simavita Appoints New Chairman
Marketwired - Wed Jan 07, 12:33PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to advise of the appointment of Mr. Michael Brown as a Director of the Company and as its Chairman of the Board. SV.VN: 0.500 (-0.050), SVA: 5.02 (+0.03)
